araag2/HINT huggingface dataset:
Clinical trial NCT01234467 (phase 2, status: completed)
Conditions: diffuse large b-cell lymphoma, lymphoma, diffuse large-cell, diffuse large-cell lymphoma, lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: bendamustine, rituximab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with previously untreated , histologically confirmed, diffuse large B-cell
             lymphoma (DLBCL), immunophenotyped for CD20

          -  Age greater than or equal to 65 years

          -  Stage II-IV

          -  Measurable disease including lesions that can be accurately measured in 2 dimensions
             by CT and have a greatest transverse diameter of 1cm or greater, and/or by bone marrow
             histopathology.

          -  ECOG performance status of 0-3

          -  Deemed poor candidate for CHOP-R due to ejection fraction less than or equal to 45%,
             ECOG performance status of 2, or in the opinion of the treating physician, patient
             would not tolerate administration of CHOP-R chemotherapy for other reasons,

          -  Life expectancy of at least 3 months;

          -  Documented negative serologic testing for HIV, Hepatitis B (unless positive due to
             prior vaccination), and hepatitis C within the year prior to enrollment

          -  Adequate bone marrow function (without transfusion support within one week of
             screening) function:

          -  Hemoglobin > 8 g/dL

          -  Absolute neutrophil count (ANC) >1000 cells/mm3

          -  Platelet count > 75,000/mm3

          -  Adequate hepatic and renal function as demonstrated by:

          -  Aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN)

          -  Total serum bilirubin < 2.5 x ULN

          -  Serum creatinine < 1.5 x ULN

          -  If sexually active male of reproductive capability, has agreed to use a medically
             accepted form of contraception from time of enrollment to completion of all follow-up
             study visits

          -  Signed an institutional review board (IRB) approved informed consent document

        Exclusion Criteria:

          -  Central nervous system involvement by lymphoma

          -  History of previous allergic reactions to compounds of similar biological or chemical
             composition as rituximab or bendamustine

          -  Medical or other condition that would represent an inappropriate risk to the patient
             or would likely compromise achievement of the primary study objective.

          -  Other active malignancies (except: non-melanoma skin cancer, cervical carcinoma in
             situ without evidence of disease, prostatic intraepithelial neoplasia without evidence
             of prostate cancer)

          -  Patients on strong inhibitors of CYP1A2.
Clinical trial NCT01314872 (phase 2, status: completed)
Conditions: urinary bladder, overactive
ICD codes: N32.81
Drugs: vibegron, tolterodine er, placebo matching vibegron, placebo matching tolterodine er
SMILES: CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  If participant is of reproductive potential, must agree to remain abstinent or use (or
             have his/her partner use) 2 acceptable methods of birth control within the projected
             duration of the study

          -  Clinical history of OAB for at least 3 months and meets either the OAB wet or OAB dry
             criteria

          -  Is able to read, understand and complete questionnaires and voiding diaries without
             assistance

          -  Is ambulatory and in good general physical and mental health

          -  No clinically significant electrocardiogram or laboratory abnormality

        Exclusion Criteria:

          -  If female, is currently pregnant or breast-feeding, or expecting to conceive within
             the projected duration of the study

          -  Evidence of diabetes insipidus, uncontrolled hyperglycemia or uncontrolled
             hypercalcemia

          -  Allergy, intolerance, or history of a significant clinical or laboratory adverse
             experience associated with any of the active or inactive components of tolterodine ER
             or vibegron (MK-4618) formulation; or has a history or active diagnosis of any
             condition contraindicated in the tolterodine ER prescribing label

          -  Has lower urinary tract pathology that could be responsible for urgency, frequency, or
             incontinence

          -  History of injury, surgery, or neurodegenerative diseases (e.g., multiple sclerosis)
             that could affect the lower urinary tract or its nerve supply

          -  History of continual urine leakage

          -  Surgery to correct stress urinary incontinence or pelvic organ prolapse within 6
             months

          -  Known history of elevated postvoid residual

          -  Bladder training or electrostimulation within 2 weeks or is planning to initiate
             either procedure during the study

          -  Active or recurrent (>6 episodes per year) urinary tract infections

          -  Current hematuria

          -  Required use of an indwelling catheter or requires intermittent catheterization

          -  History of fecal incontinence
Clinical trial NCT00277355 (phase 2/phase 3, status: completed)
Conditions: huntington disease
ICD codes: G10
Drugs: minocycline, matching placebo
SMILES: [H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18 years or older

          -  Clinical features of HD and a confirmatory family history of HD; and/or genetically
             confirmed HD

          -  Independently walking and fully self-sufficient in activities of daily living (eating,
             dressing, bathing)

          -  Able to take medication (capsules) by mouth

        Exclusion Criteria:

          -  History of known hypersensitivity or intolerability to minocycline or known allergy to
             any tetracycline

          -  History of vestibular disease

          -  Subjects with underlying hematologic, hepatic or renal disease

          -  History of systemic lupus erythematosus (SLE)
Clinical trial NCT01483742 (phase 2, status: completed)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: ro5024048, danoprevir, peginterferon alfa-2a [pegasys], ribavirin, ritonavir
SMILES: CC(C)C(=O)OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C, CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1CC2=CC=CC(F)=C2C1)C(=O)NS(=O)(=O)C1CC1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients, 18 to 65 years of age inclusive

          -  Chronic hepatitis C, genotype 1 or 4

          -  Cohort 1: Treatment-naïve for hepatitis C

          -  Cohort 2: Prior null responder to treatment with approved doses of pegylated
             interferon plus ribavirin

          -  Liver biopsy confirming cirrhosis

          -  Compensated cirrhosis (Child-Pugh A)

        Exclusion Criteria:

          -  Pregnant or lactating women or male partners of women who are pregnant

          -  History or presence of decompensated liver disease (ascites, hepatic encephalopathy,
             hepatocellular carcinoma, or bleeding esophageal varices)

          -  Cohort 2: Patients who discontinued previous pegylated interferon plus ribavirin
             treatment due to reasons other than null response

          -  History of clinically significant cardiovascular or cerebrovascular disease
Clinical trial NCT00675857 (phase 2, status: completed)
Conditions: diabetes mellitus, type 2, metabolic syndrome x
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44, E88.81, G93.41, E88.9, P19.9, E88.89, O21.1, P19.2
Drugs: nc-503 (eprodisate disodium)
SMILES: OS(=O)(=O)CCCS(O)(=O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age and gender eligibility: 30 years and older

          -  Diagnosis of Type 2 diabetes mellitus

          -  Patients treated with a stable therapeutic dose of either metformin, a sulfonylurea
             agent, or metformin in combination with a sulfonylurea agent for a minimum period of 3
             months prior to the Screening visit

          -  Patients must have HbA1C level between 7.0-10.0 %, inclusively at screening

          -  The participant must have central obesity (Waist circumference) defined per
             country/ethnic group: Europids: men ≥ 94 cm, women ≥ 80 cm; South Asian, Chinese &
             Japanese: men ≥ 90 cm, women ≥ 80 cm; and any one of the following metabolic syndrome
             characteristics at screening:

          -  Reduced HDL cholesterol ≤ 1.0 mmol/L

          -  Hypertriglyceridemia ≥ 1.7 mmol/L or treatment for dyslipidemia

          -  Hypertension: ≥ 130/85 mm Hg blood pressure or treatment with antihypertensive
             medication.

          -  Patients must have a Glomerular Filtration Rate (GFR) of ≥ 60 mL/min, and no history
             of dialysis.

        Exclusion Criteria:

          -  Patients having received insulin, thiazolidinediones (TZDs) or non-thiazolidinedione
             hypoglycemic agents other than metformin or sulfonylurea agents within three months
             prior to screening

          -  Has had, within the last 6 months, evidence of significant heart disease or stroke,
             including myocardial infarction, unstable angina, coronary bypass and/or percutaneous
             transluminal coronary angioplasty (PTCA), congestive heart failure (New York Heart
             Association Class III-IV), or severe ischemic disease

          -  Patients who have an increased red blood cell (RBC) turn-over or Thalassemia or anemia

          -  Known HIV or history of viral hepatitis type B or C.

          -  Any type of diabetes other than Type 2 diabetes

          -  Significant hepatic enzyme elevation

          -  Body mass index (BMI) of > 40kg/m2

          -  Current or previous use of oral or injectable corticosteroids, or conditions that
             require the use of corticosteroids, during the three months prior to screening
Clinical trial NCT00702156 (phase 2, status: terminated)
Conditions: heart failure, chronic obstructive pulmonary disease
ICD codes: I50.814, I09.81, I50.82, I50.89, I50.9, T86.22, I11.0, J44.9, J44.1, J44.0
Drugs: bisoprolol, placebo
SMILES: CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    inadequate patient recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  symptomatic NYHA II or III chronic heart failure

          -  left ventricular systolic dysfunction

          -  moderate or severe chronic obstructive pulmonary disease

          -  with or without significant reversibility

        Exclusion Criteria:

          -  beta-blocker contraindications

          -  non-dihydropyridine (diltiazem / verapamil) calcium channel blockers

          -  recent coronary percutaneous intervention or coronary artery bypass graft surgery

          -  haemodynamically significant valvular disease or hypertrophic cardiomyopathy.

          -  active myocarditis or pericarditis.

          -  recent cerebrovascular accident or transient ischaemic attack

          -  serious concurrent systemic disease, such as malignancy, resulting in likely reduced
             life expectancy

          -  pregnancy, childbearing potential with inadequate contraception, breast feeding
Clinical trial NCT00455897 (phase 2, status: terminated)
Conditions: lymphoma, non-hodgkin, lymphoma, b-cell, lymphoma, diffuse
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: gm-csf, chop, rituximab
SMILES: COCCC1=CC=C(OCC(O)CNC(C)C)C=C1, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    accrual was too slow. trial terminated
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed diagnosis of diffuse large B cell Non-Hodgkin's lymphoma with
             characteristic immunophenotypic profile

          -  Patient has not received any prior anti-cancer therapy for lymphoma

          -  Tumor tissue confirmed to express the cluster of differentiation antigen 20 antigen by
             flow cytometry or immunohistochemistry

          -  Measurable disease as defined by a tumor mass of 1cm or greater in one dimension

          -  Stage II (abdominal-not radiotherapy appropriate), III, or IV disease

          -  Age > 18 years

          -  Performance Status of 0-2

          -  Laboratory parameters as outlined in protocol

          -  Patient agrees to use birth control

        Exclusion Criteria:

          -  Known central nervous system involvement by lymphoma

          -  Serious uncontrolled concurrent illness such as active coronary artery disease, severe
             lung disease, heart failure, active alcohol abuse, active concurrent malignancy except
             non-melanoma skin cancer or carcinoma in situ of the cervix

          -  Any evidence of prior natural exposure to Hepatitis B

          -  Active rheumatologic disease which may be exacerbated by GM-CSF

          -  Cardiac ejection fraction less than 45%

          -  Known HIV disease

          -  Patient is pregnant or nursing

          -  Patient is receiving other investigational drugs
Clinical trial NCT00075647 (phase 2, status: completed)
Conditions: adenocarcinoma of the pancreas, recurrent pancreatic cancer, stage ii pancreatic cancer, stage iii pancreatic cancer, stage iv pancreatic cancer
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, C25.3, C25.3, C25.3, C25.3
Drugs: temsirolimus
SMILES: CN1N=NC2=C(N=CN2C1=O)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the pancreas

               -  Locally advanced or metastatic disease

          -  Radiographic evidence of disease

          -  No known brain metastases

          -  Performance status - ECOG 0-2

          -  More than 3 months

          -  WBC ≥ 3,000/mm^3

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  AST and ALT ≤ 2.5 times ULN (5 times ULN if liver metastases are present)

          -  Creatinine ≤ 1.5 mg/dL

          -  Creatinine clearance ≥ 50 mL/min

          -  No symptomatic congestive heart failure

          -  No unstable angina pectoris

          -  No cardiac arrhythmia

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Fasting serum cholesterol ≤ 350 mg/dL

          -  Fasting triglycerides ≤ 400 mg/dL

          -  No ongoing or active infection

          -  No psychiatric illness or social situation that would preclude study compliance

          -  No other concurrent uncontrolled illness

          -  No concurrent prophylactic hematopoietic colony-stimulating factors

          -  No prior chemotherapy for metastatic pancreatic cancer

          -  More than 2 months since prior adjuvant or neoadjuvant chemoradiotherapy for resected
             pancreatic cancer

               -  Must have radiographic evidence of recurrent disease

          -  More than 2 months since prior chemoradiotherapy for locally advanced pancreatic
             cancer

               -  Must have radiographic evidence of disease progression

          -  See Chemotherapy

          -  See Chemotherapy

          -  No other concurrent investigational or commercial agents or therapies for the
             malignancy

          -  No other concurrent anticancer therapy

          -  No concurrent combination antiretroviral therapy for HIV-positive patients
Clinical trial NCT00640419 (phase 2, status: completed)
Conditions: attention-deficit/hyperactivity disorder
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: abt-089, placebo
SMILES: CC1=C(OC[C@@H]2CCCN2)C=CC=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have voluntarily signed an informed consent form.

          -  Meet diagnostic criteria for attention-deficit/hyperactivity disorder (ADHD) based on
             detailed evaluation and interview with parent(s).

          -  Subject is generally in good health based on medical history, physical examination,
             clinical lab tests and ECG.

          -  Subject weights at least 37 pounds (17 kg)

          -  Female subjects of child-bearing potential must have a negative urine pregnancy test
             at screening and baseline and agree to comply with applicable contraceptive
             requirements.

          -  Subject can swallow pills and subjects and parents are able to keep required
             appointments for clinic visits and all tests, including blood draws and examinations.

        Exclusion Criteria:

          -  Subject has a current or past diagnosis of bipolar disorder, psychosis, autism,
             Asperger syndrome, pervasive developmental disorder, tics, Tourette syndrome, mental
             retardation, seizure disorder or traumatic brain injury.

          -  Current diagnosis of obsessive-compulsive disorder, eating disorder, anxiety disorder
             or depressive disorder requiring treatment of any kind.

          -  Subject has a history of, or ongoing, serious medical problem.

          -  Subject has a history of significant allergic reaction to any drug.

          -  Subject is planning to begin any type of behavioral or psychotherapy for treatment of
             ADHD.

          -  Subject requires ongoing treatment with any psychiatric medication.
Clinical trial NCT00509561 (phase 2/phase 3, status: unknown status)
Conditions: esophageal cancer
ICD codes: K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10
Drugs: capecitabine, cisplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed carcinoma of the esophagus

               -  Adenocarcinoma

               -  Squamous cell

               -  Undifferentiated carcinoma

               -  Siewert type I tumor of the gastroesophageal junction

          -  Localized, nonmetastatic disease (T1-4, N0-1) confirmed by endoscopic ultrasound (EUS)
             and spiral CT scan

          -  Total disease length (primary and lymph nodes) < 10 cm by EUS

          -  Not suitable for surgery (either for medical reasons or patient's choice)

          -  No metastatic disease (i.e., M1a or M1b according to UICC TNM version 6)

          -  No significant (> 2 cm) extension of tumor into the stomach

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-1

          -  Absolute neutrophil count ≥ 1,500/mm³

          -  White blood cell count ≥ 2,000/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Hemoglobin ≥ 10 g/dL (should be corrected to > 10 g/dL before treatment)

          -  Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  ALT/AST ≤ 2.5 times ULN

          -  Alkaline phosphatase ≤ 3 times ULN

          -  Glomerular filtration rate > 40 mL/min OR > 60 mL/min estimated by Cockcroft-Gault
             formula

          -  Adequate cardiac ejection fraction ≥ 40% by MUGA or ECHO

          -  FEV_1 ≥ 1 L by spirometry

          -  Not pregnant

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No malignancy within the past 5 years

          -  No unstable angina, uncontrolled hypertension, cardiac failure, or other clinically
             significant cardiac disease

          -  No major trauma within the past 4 weeks

          -  No known dihydropyrimidine dehydrogenase deficiency

          -  No hearing impairment or sensory-motor neuropathy > grade 2

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  At least 4 weeks since prior sorivudine and analogues

          -  At least 4 weeks since prior major surgery

          -  At least 4 weeks since prior monoclonal antibody

          -  At least 3 months since prior radiotherapy

          -  No prior treatment for invasive esophageal carcinoma or gastroesophageal junction
             carcinoma (not including photodynamic therapy or laser therapy for high-grade
             dysplasia/carcinoma in situ)

          -  No other prior treatment for this malignancy that would compromise the ability to
             deliver definitive mediastinal chemoradiotherapy or compromise survival
Clinical trial NCT00600119 (phase 2, status: completed)
Conditions: opioid induced constipation (oic)
ICD codes: K59.00, K59.09, K59.01, K59.02, K59.03, K59.04, K58.1
Drugs: placebo, nktr-118
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5
Eligibility criteria:

        Main Inclusion Criteria:

          -  18 years of age or older, male or female

          -  Receiving a stable opioid regimen

          -  Documented opioid-induced constipation

          -  Willingness to stop all laxatives and other bowel regimens. The use of constipation
             rescue medication will be allowed during the study.

        Main Exclusion Criteria:

          -  Life expectancy less than 6 months

          -  Active substance abuse

          -  Fecal incontinence, irritable bowel syndrome, inflammatory bowel disease, or other
             active medical disorders associated with diarrhea or intermittent loose stools or
             constipation

          -  Pregnant or breast-feeding

          -  Any receipt of an investigational medication within 30 days of screening

          -  History or presence of specific cardiac, neurologic, endocrine and/or psychiatric
             conditions